Patient-reported HF Symptoms Not Associated With Objective Markers of Pulmonary Congestion

Older female patient filling out questionnaire on clipboard, seated across from doctor

Researchers wondered whether the Kansas City Cardiomyopathy Questionnaire (KCCQ), a health status questionnaire for patients with heart failure, could be useful to monitor worsening pulmonary congestion remotely. They found no significant associations between KCCQ total symptom score and objective congestion markers


Brigham Offers Cutting-Edge Trials for Patients With Atrial Fibrillation

Diagram of pulsed field ablation procedure inside an esophagus

Investigators at the Brigham’s Cardiac Arrhythmia Service are participating in several clinical trials seeking to develop new techniques to improve the current standard of care for atrial fibrillation—catheter ablation using cold or heat. Service Chief William Henry Sauer, MD, discusses progress and future plans.


Optimal Treatment for Limb Threatening Ischemia Indicated in New Mass General Brigham Study

Plaque build up in artery leading to human heart anatomy shows blockage of blood

To reduce risk of amputation or death, patients with chronic limb threatening ischemia are treated with either surgical bypass or endovascular therapy. A new Mass General Brigham study compared patient outcomes between the two treatments and suggested that bypass may be the optimal treatment approach.


Improved Outcomes in Individuals With Heart Disease Who Experience Mild to Moderate Flu Vaccine Reactions

Close up of doctor administering flu shot to patient's shoulder

A new study presented by Brigham and Women’s Alexander Peikert, MD, at the AHA 2022 Scientific Sessions suggests that individuals with high-risk heart disease who experience mild to moderate reactions to the flu vaccine are less likely to be hospitalized or die from cardiopulmonary events.


Recombinant Lecithin-Cholesterol Acyltransferase Does Not Reduce Infarct Size or Plaque Volume in Acute STEMI

Coronary angiogram showing chronic total occlusion (CTO) of left anterior descending artery (LAD)

Marc S. Sabatine, MD, MPH, at Brigham and Women’s Hospital, and colleagues have completed a phase 2b trial of MEDI6012 in patients with STEMI. They report that MEDI6012 was not associated with significant reductions in infarct size or regression of noncalcified coronary plaque.


Left Ventricular Assist Device Therapy Comes of Age at the Brigham

The Brigham is giving advanced heart failure patients a new option that parallels the life prolongation of heart transplantation: implantation of a fully magnetically levitated left ventricular assist device. Mandeep R. Mehra, MD, and Akinobu Itoh, MD, PhD, are at the forefront of these efforts.


SGLT2 Inhibitors Should Be Considered Foundational Therapy in All Patients With Heart Failure

Young doctor pointing to illustration of heart anatomy to show a patient sitting in office

Scott D. Solomon, MD, director of the Clinical Trials Outcomes Center at Brigham and Women’s Hospital, and colleagues have concluded that SGLT2 inhibitors should be considered adjunctive therapy for all patients with heart failure, regardless of ejection fraction or care setting.


Dapagliflozin Safe and Effective After Hospitalization for Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Male patient lying in hospital bed smiling up at doctor standing bedside

In a prespecified secondary analysis of the DELIVER trial, Scott D. Solomon, MD, at Brigham and Women’s Hospital, and colleagues found that starting dapagliflozin during or shortly after hospitalization for HF is safe and effective for patients with mildly reduced or preserved ejection fraction.


Prospective RCT Finds Full-Dose Anticoagulation Better Than Standard Dose in Severe COVID-19

Female patient on respirator in hospital bed with two doctors monitoring

In COVID-PACT, a 2×2 factorial, randomized, controlled trial that enrolled critically ill patients with COVID-19, researchers at Brigham and Women’s Hospital determined full-dose anticoagulation was superior to standard-dose prophylaxis in reducing the proportion of patients experiencing a thrombotic event.


Brigham Cardiovascular Experts Attend AHA Scientific Sessions 2022

Audience seated looking up at male presenter at a conference

On November 5—7, 2022, experts from the Brigham’s Heart and Vascular Center will join thousands of colleagues in raising awareness and improving cardiovascular health at this year’s American Heart Association (AHA) Scientific Sessions.